Coherus Oncology
CHRS----
Coherus Oncology (CHRS)
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Coherus Oncology Analyst Rating
View MoreForecast & Rating
Jun 22, 2026Price forecast
$7.80453.19%
Forecast & RatingStrong buy
7analysts
- Strong buy71.43%
- Buy14.29%
- Hold14.29%
- Sell0.00%
- Strong sell0.00%
News
- StockTitan · 2 days ago, 04:36 AM
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 | CHRS Stock News
- Global Report · Jul 14 at 06:47 AM
Unbundling the Value Chain: Business Models from Digital Infrastructure to Physical Scale
- Global Report · Jul 9 at 05:03 AM
Toyota's USD 3.6B Expansion and Oil Sector Buybacks Highlight Capital Shifts Beyond Big Tech
- StockTitan · Jun 23 at 05:00 AM
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) | CHRS Stock News
- benzinga_article · May 12 at 10:51 AM
Coherus Oncology shares are trading lower after the company reported mixed Q1 financial results.
- StockTitan · May 4 at 12:30 AM
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 | CHRS Stock News
